Factors associated with antibody titer levels among an occupational cohort of fully vaccinated individuals and subsequent risk of COVID-19 infection: A cohort study.

Autor: Wasserman EB; IQVIA Real-World Solutions, Durham, North Carolina, USA., Sills AK; National Football League, New York, New York, USA., Martins D; Atlantic Sports Health, Morristown Medical Center, Morristown, New Jersey, USA., Casolaro A; MD2 McLean, Virginia Hospital Center, Tysons Corner, Virginia, USA., Walton P; Williamson Health, Franklin, Tennessee, USA., Anderson D; Duke University School of Medicine, Durham, North Carolina, USA.; Infection Control Education for Major Sports, Chapel Hill, North Carolina, USA., Pasha S; IQVIA Real-World Solutions, Durham, North Carolina, USA., O'Neal C; Louisiana State University Health Sciences Center, Baton Rouge, Louisiana, USA., Eichner D; Sports Medicine Research and Testing Laboratory, South Jordan, Utah, USA., Osterholm M; Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, Minnesota, USA., Mancell J; University of Tennessee Health Science Center, Memphis, Tennessee, USA., Mack CD; IQVIA Real-World Solutions, Durham, North Carolina, USA.
Jazyk: angličtina
Zdroj: Journal of medical virology [J Med Virol] 2023 Aug; Vol. 95 (8), pp. e28999.
DOI: 10.1002/jmv.28999
Abstrakt: This study (1) determined the association of time since initial vaccine regimen, booster dose receipt, and COVID-19 history with antibody titer, as well as change in titer levels over a defined period, and (2) determined risk of COVID-19 associated with low titer levels. This observational study used data from staff participating in the National Football League COVID-19 Monitoring Program. A cohort of staff consented to antibody-focused sub-study, during which detailed longitudinal data were collected. Among all staff in the program who received antibody testing, COVID-19 incidence following antibody testing was determined. Five hundred eighty-six sub-study participants completed initial antibody testing; 80% (469) completed follow-up testing 50-101 days later. Among 389 individuals who were not boosted at initial testing, the odds of titer < 1000 AU/mL (vs. ≥1000 AU/mL) increased 44% (odds ratio [OR] = 1.44, 95% confidence interval [CI]: 1.18-1.75) for every 30 days since final dose. Among 126 participants boosted before initial testing with no COVID-19 history, 125 (99%) had a value > 2500 AU/ml; 86 (96%) of 90 tested at follow-up and did not develop COVID-19 in the interim remained at that value. One thousand fifty-seven fully vaccinated (330 [29%] boosted at antibody test) individuals participating in the monitoring program were followed to determine COVID-19 status. Individuals with titer value < 1000 AU/mL had twice the risk of COVID-19 as those with >2500 AU/mL (HR = 2.02, 95% CI: 1.28-3.18). Antibody levels decrease postvaccination; boosting increases titer values. While antibody level is not a clear proxy for infection immunity, lower titer values are associated with higher COVID-19 incidence, suggesting increased protection from boosters.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: